Analysis of sugar structures bound to antibodies in different body compartments.

Glycosylation of Antibodies; Dynamics in Biofluids (GLADBio) - Glycosylation of antibodies; dynamics in biofluids

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON58013

Enrollment

Registered

2025-05-21

Start date

2026-03-26

Completion date

Unknown

Last updated

2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

antibody, immunoglobulin, Ig antibody

Interventions

None listed

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: between 18 and 30 years oldMale or Female sexgenerally healthy without substantial comorbidities, especially no primary or secondary immunodeficiencies. 

Exclusion criteria

Exclusion criteria: Current or previous pregnanciescurrent smokers, defined as individuals who report regular use of tobacco products (including vapes) within the past 12 months.Diagnosed with chronic rhinosinusitis, allergic rhinitis and/or allergic asthmaUse of anti-histamines to relieve allergic/hay fever symptomsUse of oral corticosteroids or antibiotics in the past 6 weeksChronic nasal corticosteroid use (>3 months)Immunocompromised individuals (with primary immune deficiency or secondary immune deficiency) Vaccination with any vaccine <3 months before inclusionSymptoms of a respiratory tract infection or common cold in the past 4 weeks History of severe nose bleedsUse of anticoagulantsInability to provide informed consent or visit LUMC for study procedures

Design outcomes

Primary

Measure	Time frame
Main study parameter/endpoint: The percentage composition of IgG glycoforms in the biological fluids blood and nasal lining fluid.	—

Secondary

Measure	Time frame
Secondary endpointsThe percentage composition of IgA, IgM, IgD and IgE glycoforms in the biological fluids blood and nasal lining fluid. The percentage composition of antibody glycoforms within various biological fluids (blood, stool, nasal lining fluids, urine, saliva and tears).Diurnal and weekly dynamics of antibody glycoforms within the various biological fluids. Comparison of antibody glycoforms between different handled samples.Explorative endpointsDetermination of secreted immune mediators (e.g. cytokines, antimicrobial defence molecules and metabolites) in various biological fluids and associate this with observed antibody glycoforms.Associate microbiota in stool, nasal lining fluids, and saliva with antibody glycoforms and secreted immune mediatorsAssociated viral load in stool, nasal lining fluids, and saliva with antibody glycoforms and secreted immune mediators.	—

Measure

Time frame

Secondary endpointsThe percentage composition of IgA, IgM, IgD and IgE glycoforms in the biological fluids blood and nasal lining fluid. The percentage composition of antibody glycoforms within various biological fluids (blood, stool, nasal lining fluids, urine, saliva and tears).Diurnal and weekly dynamics of antibody glycoforms within the various biological fluids. Comparison of antibody glycoforms between different handled samples.Explorative endpointsDetermination of secreted immune mediators (e.g. cytokines, antimicrobial defence molecules and metabolites) in various biological fluids and associate this with observed antibody glycoforms.Associate microbiota in stool, nasal lining fluids, and saliva with antibody glycoforms and secreted immune mediatorsAssociated viral load in stool, nasal lining fluids, and saliva with antibody glycoforms and secreted immune mediators.

—

Countries

Netherlands

Contacts

Public ContactW Hoepel

Leids Universitair Medisch Centrum

IMMUonderzoek@lumc.nl0715266162

Outcome results